Discontinue Risperidone, Taper Mirtazapine Gradually, Start Citalopram with Caution, and Reconsider the Depakote/Seroquel Combination
Your proposed plan requires significant modification: discontinue risperidone appropriately, taper mirtazapine slowly rather than abruptly stopping it, start citalopram 10 mg for depression but screen carefully for bipolar disorder first, and reconsider the Depakote/Seroquel combination as quetiapine monotherapy may be sufficient for mood stabilization in this elderly patient.
Critical Concerns with Your Proposed Plan
1. Abrupt Mirtazapine Discontinuation is Inappropriate
Do not abruptly discontinue mirtazapine after over a year of use. Antidepressants stopped abruptly commonly cause withdrawal symptoms including dysphoric mood, irritability, agitation, dizziness, sensory disturbances, anxiety, confusion, insomnia, and emotional lability 1. These symptoms can last days to months and may be severe 2.
Taper mirtazapine over weeks to months:
- For a patient on mirtazapine long-term, reduce the dose by 25-50% every 2-4 weeks initially 3
- As you approach lower doses, consider even smaller decrements (e.g., 25% reductions every 2-4 weeks)
- Monitor closely for withdrawal symptoms at each step
- If intolerable symptoms emerge, resume the previous dose and taper more gradually 1
2. Citalopram Requires Bipolar Disorder Screening
Before starting citalopram, you must screen this patient for bipolar disorder. She has mood instability, fluctuation, and behavioral aggression—all potentially consistent with bipolar disorder 1. The FDA label explicitly warns that treating a bipolar patient with an antidepressant alone may precipitate a manic/mixed episode 1.
Required screening includes:
- Detailed psychiatric history focusing on prior manic/hypomanic episodes
- Family history of bipolar disorder, suicide, and depression
- History of antidepressant-induced mood switches or activation
Note: Citalopram is not FDA-approved for bipolar depression 1. If bipolar disorder is suspected or confirmed, your medication strategy needs fundamental revision.
3. Quetiapine Monotherapy May Be Sufficient
The evidence suggests quetiapine alone has robust efficacy for bipolar depression and mood stabilization 4. Adding Depakote 125 mg twice daily (total 250 mg/day) is a subtherapeutic dose for mood stabilization and adds polypharmacy burden in a 72-year-old.
Consider this alternative approach:
- Use quetiapine monotherapy at therapeutic doses (300 mg at bedtime, which can be titrated from your proposed 25 mg starting dose)
- The 300 mg and 600 mg doses showed comparable efficacy in bipolar depression trials 4
- Quetiapine addresses depression, mood instability, aggression, anxiety, and insomnia simultaneously
- This reduces polypharmacy and drug-drug interaction risks
4. Drug-Drug Interaction Concerns
If you proceed with the Depakote/quetiapine combination, be aware that valproic acid can alter quetiapine metabolism, potentially increasing adverse effects 5. Therapeutic drug monitoring may be warranted if combining these agents, particularly in an elderly patient 5.
5. Risperidone Discontinuation Approach
Taper risperidone gradually despite only 2 weeks of use. Antipsychotics should be reduced slowly over weeks to months to avoid withdrawal syndromes, relapse, and rebound symptoms 6. Even short-term use warrants gradual discontinuation.
Suggested approach:
- Reduce risperidone by 25-50% every 3-7 days
- Monitor for withdrawal symptoms and behavioral changes
- Complete discontinuation over 1-2 weeks minimum
Recommended Modified Plan
Step 1 (Weeks 1-2): Begin tapering risperidone while starting quetiapine 25 mg at bedtime. Increase quetiapine by 25-50 mg every 2-3 days as tolerated, targeting 300 mg at bedtime.
Step 2 (Weeks 2-4): Once risperidone is discontinued and quetiapine is at therapeutic dose, assess response. If mood instability, aggression, and insomnia improve, quetiapine monotherapy may be sufficient.
Step 3 (Weeks 4-8): If depressive symptoms persist despite therapeutic quetiapine and bipolar disorder has been ruled out, begin mirtazapine taper (reduce by 25-50% every 2-4 weeks) while simultaneously starting citalopram 10 mg.
Step 4 (Ongoing): If quetiapine monotherapy is insufficient for mood stabilization after 4-6 weeks at therapeutic dose, then consider adding a mood stabilizer. However, use therapeutic doses of valproate (typically 750-2000 mg/day for mood stabilization, not 250 mg/day).
Critical Caveats for Elderly Patients
Black box warning: Antipsychotics increase mortality risk in elderly patients with dementia-related psychosis 7. If dementia is present, antipsychotics should only be used when symptoms are severe, dangerous, or cause significant distress, after nonpharmacological interventions have been tried 7.
Start low, go slow: Your proposed quetiapine doses (25 mg bedtime, 12.5 mg noon) are appropriately conservative starting points, but therapeutic efficacy for mood symptoms typically requires 300-600 mg daily 4.
Monitor metabolic effects: Quetiapine can cause weight gain, diabetes, and dyslipidemia—particularly important in elderly patients.
QTc prolongation risk: Citalopram has dose-dependent QTc prolongation; maximum dose in patients >60 years is 20 mg/day 1. Obtain baseline ECG.
What Not to Do
- Do not abruptly stop mirtazapine—this invites withdrawal syndrome that may worsen her behavioral symptoms
- Do not start citalopram without bipolar screening—risk of mood destabilization
- Do not use subtherapeutic Depakote doses—either use therapeutic doses or don't use it at all
- Do not add multiple medications simultaneously—makes it impossible to determine what helps or harms
The safest approach prioritizes quetiapine monotherapy first, with sequential medication adjustments based on response, rather than simultaneous polypharmacy changes in an elderly patient with complex psychiatric symptoms.